| Name | Harmons Pharmacy #21 |
|---|---|
| Organization Name | Harmon City Inc |
| Location | 3270 S 1300 E, Salt Lake City, Utah 84106 |
| Type | Community/Retail Pharmacy |
| Phone | (801) 487-5461 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
It has been more than 20 years since scientists discovered that mutations in the gene huntingtin cause the devastating progressive neurological condition Huntington's disease, which involves involuntary movements, emotional disturbance and cognitive impairment.
Since before the 1300s, people living in many parts of Africa have been dying from a disease known as sleeping sickness. Despite public health campaigns that explain ways to stop infection—primarily by killing the disease-spreading tsetse fly—successful eradication has remained out of reach. That's partly because epidemiologists can't predict where cases will emerge next.
A study conducted by researchers at Carnegie Mellon University and the University of Pittsburgh involving an amnesia-inducing drug has shed light on how we form new memories.
› Verified 2 days ago
| NPI Number | 1902819832 |
| Organization Name | HARMON CITY INC |
| Doing Business As | HARMONS PHARMACY #21 |
| Type | Community/Retail Pharmacy |
| Address | 3270 S 1300 E, Salt Lake City, UT 84106 |
| Phone Number | 801-487-5461 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
It has been more than 20 years since scientists discovered that mutations in the gene huntingtin cause the devastating progressive neurological condition Huntington's disease, which involves involuntary movements, emotional disturbance and cognitive impairment.
Since before the 1300s, people living in many parts of Africa have been dying from a disease known as sleeping sickness. Despite public health campaigns that explain ways to stop infection—primarily by killing the disease-spreading tsetse fly—successful eradication has remained out of reach. That's partly because epidemiologists can't predict where cases will emerge next.
A study conducted by researchers at Carnegie Mellon University and the University of Pittsburgh involving an amnesia-inducing drug has shed light on how we form new memories.
› Verified 2 days ago
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
It has been more than 20 years since scientists discovered that mutations in the gene huntingtin cause the devastating progressive neurological condition Huntington's disease, which involves involuntary movements, emotional disturbance and cognitive impairment.
Since before the 1300s, people living in many parts of Africa have been dying from a disease known as sleeping sickness. Despite public health campaigns that explain ways to stop infection—primarily by killing the disease-spreading tsetse fly—successful eradication has remained out of reach. That's partly because epidemiologists can't predict where cases will emerge next.
A study conducted by researchers at Carnegie Mellon University and the University of Pittsburgh involving an amnesia-inducing drug has shed light on how we form new memories.
› Verified 2 days ago
Handspring Clinical Services Type: Prosthetic/Orthotic Supplier Location: 750 E 100 S, Salt Lake City, Utah 84102 Phone: (801) 328-9728 | |
Accredo Health Group Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3488 S Main St, Salt Lake City, Utah 84115 Phone: (801) 832-0222 | |
Albertson's Pharmacy #1708 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 729 N Redwood Rd, Salt Lake City, Utah 84116 Phone: (801) 532-3795 | |
Alpine Home Medical Equipment Llc Type: DME Supplier - Oxygen Equipment & Supplies Location: 4030 S State St, Salt Lake City, Utah 84107 Phone: (801) 463-0044 | |
Amerita, Inc. Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2446 S Progress Dr, Salt Lake City, Utah 84119 Phone: (801) 908-6100 |